Journal Watch · Lancet Diabetes & Endocrinology · 2026

Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial.

Due to dropouts, we cannot draw firm conclusions on the effects of GIP as add-on to placebo.<h4>Funding</h4>Novo Nordisk.

Helsted MM, Fonnesbech-Wulff C, Schaltz NL et al.Lancet Diabetes & Endocrinology5 min readPharma relevance 95/100

DOI: 10.1016/s2213-8587(26)00075-6PMID: 42173109Study type: randomised / controlled clinical trial

TL;DR

Due to dropouts, we cannot draw firm conclusions on the effects of GIP as add-on to placebo.<h4>Funding</h4>Novo Nordisk.

Key findings

  • Fasting concentrations of intact (bioactive) GIP at the end of treatment on week 14 were mean 7 pmol/L (SD 4) in the placebo plus placebo group, 45 pmol/L (43) in the placebo plus GIP group, 10 pmol/L (6) in the semaglutide plus placebo group, and 85 pmol/L (92) in the semaglutide plus GIP group; whereas fasting concentrations of total GIP were 14 pmol/L (7), 375 pmol/L (377), 18 pmol/L (19), and 527 pmol/L (338), respectively.
  • The estimated effect of GIP on change in 14-day mean sensor-detected glucose from baseline to end of treatment was 0·80 mmol/L (97·5% CI -0·18 to 1·80; p=0·13 in the placebo plus GIP vs placebo plus placebo groups) and 0·05 mmol/L (-0·85 to 0·95; p=1·00 in the semaglutide plus GIP vs semaglutide plus placebo groups).
  • Injection site reactions were the most common adverse event (22 [36%]).
  • Gastrointestinal adverse events were more frequent with semaglutide (nine [60%] with placebo plus placebo, 11 [69%] with placebo plus GIP, 11 [73%] with semaglutide plus placebo, and 12 [80%] with semaglutide plus GIP).<h4>Interpretation</h4>6 weeks of subcutaneous GIP infusion as add-on to placebo or semaglutide did not improve glycaemic control in individuals with type 2 diabetes at the prespecified target of 1·50 mmol/L.
  • Due to dropouts, we cannot draw firm conclusions on the effects of GIP as add-on to placebo.<h4>Funding</h4>Novo Nordisk.

Numbers at a glance (from the abstract)

5%16%36%64%60%69%73%80%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

The primary outcome was change in 14-day mean glucose concentration assessed by continuous glucose monitoring from baseline to the end of treatment at 14 weeks, assessed in the efficacy population. This study is registered at ClinicalTrials.gov, NCT05078255 (completed).<h4>Findings</h4>Between Jan 31, 2022, and Sept 4, 2024, we assessed 134 individuals with type 2 diabetes for eligibility, of whom 73 were ineligible. We enrolled and randomly assigned 61 participants (15 to placebo plus placebo, 16 to placebo plus GIP, 15 to semaglutide plus placebo, and 15 to semaglutide plus GIP). Ten (16%) participants discontinued the study. Participants had a median age of 64·0 years (IQR 60·0-68·0), HbA<sub>1c</sub> of 54·0 mmol/mol (49·0-60·0), diabetes duration of 6·3 years (4·2-9·8), and a mean BMI of 31·6 kg/m<sup>2</sup> (SD 4·8). 22 (36%) participants were female and 39 (64%) were male and all self-reported as White.

Full abstract (original)

Background: <h4>Background</h4>The long-term glycaemic effects of glucose-dependent insulinotropic polypeptide (GIP) remain unclear. We aimed to assess whether a 6-week subcutaneous infusion of GIP alone and in combination with the GLP-1 receptor agonist semaglutide would enhance glycaemic control in individuals with type 2 diabetes.<h4>Methods</h4>This single-centre, double-blind, parallel-group, randomised, placebo-controlled trial was conducted at the Center for Clinical Metabolic Research (Hellerup, Denmark). Inclusion criteria were age 18-74 years; a diagnosis of type 2 diabetes for at least 6 months; stable treatment; HbA<sub>1c</sub> of 6·5-10·5% (48-91 mmol/mol); and a BMI of 25-50 kg/m<sup>2</sup>. Participants were randomly assigned (1:1:1:1), using a block randomisation list, to receive either placebo plus placebo, placebo plus GIP, semaglutide plus placebo, or semaglutide plus GIP (all self-administered subcutaneously). The regimen was 8-week semaglutide or placebo run-in period (4 weeks at 0·25 mg then 4 weeks at 0·50 mg once per week), after which participants continued 0·50 mg semaglutide or placebo for an additional 6 weeks while receiving continuous subcutaneous infusions of GIP or placebo (16 pmol/kg per min). Participants and investigators were masked to treatment assignment.

What they did: The primary outcome was change in 14-day mean glucose concentration assessed by continuous glucose monitoring from baseline to the end of treatment at 14 weeks, assessed in the efficacy population. This study is registered at ClinicalTrials.gov, NCT05078255 (completed).<h4>Findings</h4>Between Jan 31, 2022, and Sept 4, 2024, we assessed 134 individuals with type 2 diabetes for eligibility, of whom 73 were ineligible. We enrolled and randomly assigned 61 participants (15 to placebo plus placebo, 16 to placebo plus GIP, 15 to semaglutide plus placebo, and 15 to semaglutide plus GIP). Ten (16%) participants discontinued the study. Participants had a median age of 64·0 years (IQR 60·0-68·0), HbA<sub>1c</sub> of 54·0 mmol/mol (49·0-60·0), diabetes duration of 6·3 years (4·2-9·8), and a mean BMI of 31·6 kg/m<sup>2</sup> (SD 4·8). 22 (36%) participants were female and 39 (64%) were male and all self-reported as White.

Results & conclusions: Fasting concentrations of intact (bioactive) GIP at the end of treatment on week 14 were mean 7 pmol/L (SD 4) in the placebo plus placebo group, 45 pmol/L (43) in the placebo plus GIP group, 10 pmol/L (6) in the semaglutide plus placebo group, and 85 pmol/L (92) in the semaglutide plus GIP group; whereas fasting concentrations of total GIP were 14 pmol/L (7), 375 pmol/L (377), 18 pmol/L (19), and 527 pmol/L (338), respectively. The estimated effect of GIP on change in 14-day mean sensor-detected glucose from baseline to end of treatment was 0·80 mmol/L (97·5% CI -0·18 to 1·80; p=0·13 in the placebo plus GIP vs placebo plus placebo groups) and 0·05 mmol/L (-0·85 to 0·95; p=1·00 in the semaglutide plus GIP vs semaglutide plus placebo groups). Injection site reactions were the most common adverse event (22 [36%]). Gastrointestinal adverse events were more frequent with semaglutide (nine [60%] with placebo plus placebo, 11 [69%] with placebo plus GIP, 11 [73%] with semaglutide plus placebo, and 12 [80%] with semaglutide plus GIP).<h4>Interpretation</h4>6 weeks of subcutaneous GIP infusion as add-on to placebo or semaglutide did not improve glycaemic control in individuals with type 2 diabetes at the prespecified target of 1·50 mmol/L. Due to dropouts, we cannot draw firm conclusions on the effects of GIP as add-on to placebo.<h4>Funding</h4>Novo Nordisk.

Abstract © the authors / Lancet Diabetes & Endocrinology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/s2213-8587(26)00075-6 · PubMed 42173109.

Why it matters for pharma & biotech

  • Directly relevant to teams in metabolic / GLP-1 therapeutics, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: metabolic / GLP-1 therapeutics · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Lancet Diabetes & Endocrinology study find?

Due to dropouts, we cannot draw firm conclusions on the effects of GIP as add-on to placebo.<h4>Funding</h4>Novo Nordisk.

What type of study is this?

It is a randomised / controlled clinical trial, published in Lancet Diabetes & Endocrinology in 2026. The primary outcome was change in 14-day mean glucose concentration assessed by continuous glucose monitoring from baseline to the end of treatment at 14 weeks, assessed in the efficacy population.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/s2213-8587(26)00075-6. PubMed ID: 42173109. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Helsted MM, Fonnesbech-Wulff C, Schaltz NL et al.. Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial.. Lancet Diabetes & Endocrinology (2026). DOI: 10.1016/s2213-8587(26)00075-6.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/effects-of-a-6-week-subcutaneous-infusion-of-native-gip-alone-or-as-add-000756/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides